Synvista Therapeutics

SYNI · OTC

$0.00+$0.00 (+0.00%)TodayMarket open · Dec 30, 11:10 AM ET · Delayed 15 min

No price history for this range.

About SYNI

Synvista Therapeutics, Inc. is a biotechnology company, which engages in the development of diagnostic tests and pharmaceutical drugs for the treatment of diabetes. The company is headquartered in Montvale, New Jersey and currently employs 9 full-time employees. The firm's lead drug candidate, alagebrium chloride or alagebrium, is an advanced glycation end-product crosslink breaker being developed for diastolic heart failure (DHF). Synvista is also managing a discovery and development program to produce small molecule drugs that mimic the enzyme glutathione peroxidase (GPx). One of the Company’s GPx mimetics, ALT-2074, is in Phase II clinical trials.

Employees: 9
Headquarters: Montvale, New Jersey
Listed: Nov 1, 1991
Sector: Health Care
Industry: Pharmaceuticals

Leadership

Synvista Therapeutics executives
Name	Title	Since	Age
Noah Berkowitz	—	2006	49
Wendy Milici	—	—	40
David Tantillo	—	—	—
John Bedard	—	—	62
Mary Tanner	—	—	—
Wayne Yetter	—	—	72
William Federici	—	—	58

Similar companies

Companies in the same industry as Synvista Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.